Prevalence of hyperprolactinemia in polycystic ovary syndrome and its clinical correlates

Kirti Chaudhary; Somenath Ghosh; Priyanka Mitra; Archana Pradhan

doi:10.18203/2320-1770.ijrcog20252737

Authors

Kirti Chaudhary Department of Obstetrics and Gynecology, Tata Motors Hospital, Jamshedpur, Jharkhand, India
Somenath Ghosh Department of Obstetrics and Gynecology, Tata Motors Hospital, Jamshedpur, Jharkhand, India
Priyanka Mitra Department of Obstetrics and Gynecology, Tata Motors Hospital, Jamshedpur, Jharkhand, India
Archana Pradhan Department of Obstetrics and Gynecology, Tata Motors Hospital, Jamshedpur, Jharkhand, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20252737

Keywords:

PCOS, Hyperprolactinemia, BMI, Hyperandrgenism, Alopecia, Menstrual irregularity

Abstract

Background: Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age. Hyperprolactinemia may co-exist with PCOS due to hypothalamic-pituitary dysfunction or relative hyperestrogenemia, but the association remains unclear.

Methods: This cross-sectional study included 110 women diagnosed with PCOS using Rotterdam criteria. Serum prolactin levels were assessed and correlated with body mass index (BMI), age, menstrual irregularities, and hyperandrogenic features. Statistical analysis was performed using SPSS version 24.

Results: The mean age of participants was 24.05±5.17 years, and mean BMI was 24.63±3.13 kg/m². Hyperprolactinemia (prolactin >25 ng/ml) was found in 57.27% of PCOS patients, with a mean prolactin level of 29.61±16.55 ng/ml. Serum prolactin showed a significant positive correlation with BMI (p=0.0022) and age (p=0.0009). Among hyperandrogenic features, alopecia was significantly associated with hyperprolactinemia (p=0.0231). Oligomenorrhea/amenorrhea was present in 56.57% of those with hyperprolactinemia, but without statistical significance (p=0.8267).

Conclusions: Hyperprolactinemia was prevalent in over half of PCOS patients and correlated positively with BMI and age. Alopecia showed a significant association with elevated prolactin levels. These findings highlight the importance of screening for hyperprolactinemia in PCOS and call for further research into its pathophysiological role.

Metrics

Metrics Loading ...

References

Delcour C, Robin G, Young J, Dewailly D. PCOS and Hyperprolactinemia: what do we know in 2019. Clinical Medicine Insights: Reproductive Health. 2019;13:1921. DOI: https://doi.org/10.1177/1179558119871921

Davoudi Z, Araghi F, Vahedi M, Mokhtari N, Gheisari M. Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management. Acta Bio Medica: Atenei Parmensis. 2021;92(5):67.

Mahboobifard F, Rahmati M, Amiri M, Azizi F, Tehrani FR. To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study. Adv Med Sci. 2022;67(1):79-86. DOI: https://doi.org/10.1016/j.advms.2021.12.003

Yatavelli RKR, Bhusal K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL). 2023.

Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arquivos Brasileiros de Endocrinologia & Metabologia. 2014;58(1):9–22. DOI: https://doi.org/10.1590/0004-2730000003002

Vilar L, Abucham J, Albuquerque JL. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236–63. DOI: https://doi.org/10.20945/2359-3997000000032

Pignatelli D, Pereira SS, Kandaraki E. The pathogenic role of androgen excess in PCOS. Polycystic Ovary Syndrome. 2022;7:55–71. DOI: https://doi.org/10.1016/B978-0-12-823045-9.00017-1

Sharma T book of gynecology JB. Menstrual disorders and pelvic pain. In: Textbook of gynecology. Sirmour, Himachal Pradesh, India: Arya Publication Company, 2022, pp. 119–60.

Mayo Clinic. Polycystic Ovary Syndrome (PCOS) - Symptoms and Causes [Internet]. Mayo Clinic. 2022. Available at: https://www.mayoclinic.org/diseases-conditions/pcos/symptoms-

Latha P, Ravi B V, Sadaria R. Study of TSH and prolactin in PCOS subjects: A case control study. Int J Clin Biochem Res. 2021;8(1):62-5. DOI: https://doi.org/10.18231/j.ijcbr.2021.013

Naz MSG, Tehrani FR, Majd HA, Ahmadi F, Ozgoli G, Fakari FR, et al. The prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis. Int J Reprod Biomed. 2019;17(8):533-42. DOI: https://doi.org/10.18502/ijrm.v17i8.4818

Hassan MF. The frequency of elevated prolactin level in polycystic ovary syndrome women (PCOS) and its effect on pregnancy rate. Global J Public Health Med. 2020;2(1):109-17. DOI: https://doi.org/10.37557/gjphm.v2i1.28

Lavanya K, Palaniappan N, Vinodhini VM, Kumar M, Silambanan S. Association of prolactin and insulin with obesity in women with polycystic ovarian syndrome. Biomedicine. 2022;42(6):1166-71. DOI: https://doi.org/10.51248/.v42i6.1613

Kamrul-Hasan AB, Aalpona FT. Metabolic association of serum prolactin in polycystic ovary syndrome: A retrospective analysis of 840 patients in Bangladesh. Endoc Metab Sci. 2024;14:10015. DOI: https://doi.org/10.1016/j.endmts.2023.100153

Moria Y, Kortbawi R, El-Asmar N, Arafah BM. Increased androgen secretion in patients with prolactinomas: the impact of altered HPA function. Pituitary. 2019;22:170-8. DOI: https://doi.org/10.1007/s11102-019-00948-w